XOMA Share Price

Open 7.52 Change Price %
High 7.55 1 Day 0.05 0.67
Low 7.39 1 Week 0.21 2.87
Close 7.52 1 Month 0.25 3.44
Volume 12514 1 Year 6.93 1174.58
52 Week High 8.13
52 Week Low 0.34
XOMA Important Levels
Resistance 2 7.67
Resistance 1 7.61
Pivot 7.49
Support 1 7.43
Support 2 7.37
NASDAQ USA Most Active Stocks
DCTH 0.15 -11.76%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
QQQ 141.23 -0.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
FALC 0.25 38.89%
VRTA 4.50 38.46%
ESMC 0.13 30.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
STXS 0.68 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

XOMA Corporation (NASDAQ: XOMA)

XOMA Technical Analysis 5
As on 18th Aug 2017 XOMA Share Price closed @ 7.52 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.54 & Strong Buy for SHORT-TERM with Stoploss of 7.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
XOMA Target for August
1st Target up-side 7.67
2nd Target up-side 8
3rd Target up-side 8.32
1st Target down-side 6.75
2nd Target down-side 6.42
3rd Target down-side 6.1
XOMA Other Details
Segment EQ
Market Capital 188892816.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.xoma.com
XOMA Address
XOMA
2910 Seventh Street
Berkeley, CA 94710
United States
Phone: 510-204-7200
XOMA Latest News
Value Composition in Focus For XOMA Corporation (NasdaqGM:XOMA) and EVINE Live ...   Stock Daily Review   - 19th Aug 17
Breaking: XOMA Corporation (NASDAQ:XOMA) Stock Through Resistance ...   CML News   - 16th Aug 17
XOMA Corporation (XOMA) Receiving Favorable News Coverage, Study Shows   BNB Daily (blog)   - 16th Aug 17
XOMA Reports Second Quarter 2017 Financial Results   GlobeNewswire (press release)   - 09th Aug 17
XOMA: Another Ligand In The Making?   Seeking Alpha   - 28th Jul 17
XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets ...   GlobeNewswire (press release)   - 18th May 17
XOMA Corporation (NASDAQ:XOMA) Is A Changed Company: Here's How And Why   Insider Financial   - 20th Apr 17
XOMA Appoints Matthew Perry to its Board of Directors   GlobeNewswire (press release)   - 16th Feb 17
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from ...   GlobeNewswire (press release)   - 22nd Dec 16
XOMA Announces Reverse Stock Split   GlobeNewswire (press release)   - 15th Oct 16
Interactive Technical Analysis Chart XOMA Corporation ( XOMA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on XOMA Corporation
XOMA Business Profile
XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company�s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company�s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. On January 17, 2012, it announced that it had acquired certain the United States rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON (perindopril erbumine), a marketed angiotensin converting enzyme (ACE) inhibitor, and three fixed-dose combination (FDC) product candidates where a form of perindopril (perindopril arginine) is combined with another active ingredient.